Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Chem Biol Drug Des. 2013 Aug;82(2):131–139. doi: 10.1111/cbdd.12146

Figure 2.

Figure 2

Figure 2

Effect of active compounds on EpCAM expression in Hep3B cells.

Cells were treated for 1-2 d with the indicated compound followed by harvesting as assessment of EpCAM expression by flow cytometry using APC-labeled anti-EpCAM (clone EBA-1).

A: untreated, B: AV606 (1 μM, 2 d), C: fiduxosin (10 μM, 2 d), D: NSC45291(10 μM, 2 d), E: pimozide (10 μM, 2 d).

“FL4-H” = fluorescence intensity (APC channel).

In panel F, data from flow cytometry experiments were analyzed for % of cells expressing any EpCAM and for median expression of EpCAM in the cell population. All results were normalized to the value for control (untreated) cells and presented at treated/control ratio (T/C).

Error bars represent sd or range (n = 2-4).

Open bars: total EpCAM-positive cells, 1 d incubation with compounds

Light gray bars: total EpCAM-positive cells, 2 d incubation with compounds

Dark gray bars: median EpCAM expression, 1 d incubation with compounds

Black bars: median EpCAM expression, 2 d incubation with compounds.

*p < 0.05, students t-test. For 2 d, data are insufficient for t-test analysis.